|
Originally published In Press as doi:10.1074/jbc.M106163200 on August 10, 2001
J. Biol. Chem., Vol. 276, Issue 45, 42213-42218, November 9, 2001
Cloning and Characterization of a Novel Protein Kinase That
Impairs Osteoblast Differentiation in Vitro*
Ann E.
Kearns §,
Megan M.
Donohue¶§,
Bharati
Sanyal , and
Marie B.
Demay¶
From the Division of Endocrinology, Diabetes,
Metabolism and Nutrition, Mayo Clinic, Rochester, Minnesota 55905 and
¶ Endocrine Unit, Massachusetts General Hospital, Harvard Medical
School, Boston, Massachusetts 02114
Received for publication, July 2, 2001, and in revised form, August 6, 2001
 |
ABSTRACT |
The bone morphogenic proteins (BMPs) play a key
role in skeletal development and patterning. Using the technique of
differential display polymerase chain reaction (ddPCR), we have
identified a novel gene whose expression is increased during
BMP-2-induced differentiation of the prechondroblastic cell line,
MLB13MYC clone 17, to an osteoblastic phenotype. The
6.5-kilobase mRNA recognized by this ddPCR product is
increased 10-fold by BMP-2 treatment of the MLB13MYC clone 17 cells.
The mRNA recognized by this ddPCR product is also increased as
MC3T3-E1 cells recapitulate the program of osteoblast differentiation
during prolonged culture. The full-length transcript corresponding to
this ddPCR product was cloned from a MLB13MYC clone 17 cell cDNA
library. Analysis of the deduced amino acid sequence demonstrated that
this gene encodes a novel 126-kDa putative serine/threonine protein
kinase containing a nuclear localization signal. The kinase domain,
expressed in Escherichia coli, is capable of
autophosphorylation as well as phosphorylation of myelin basic protein.
The gene was, therefore, named BIKe
(BMP-2-Inducible Kinase). The BIKe nuclear localization signal
is able to direct green fluorescent protein to the nucleus in
transfected COS-7 cells. When stably expressed in MC3T3-E1 cells, BIKe
significantly decreases alkaline phosphatase activity and osteocalcin
mRNA levels and retards mineral deposition relative to vector
control. This novel kinase, therefore, is likely to play an
important regulatory role in attenuating the program of osteoblast differentiation.
 |
INTRODUCTION |
Numerous investigations have been directed at elucidating factors
that regulate osteoblast differentiation (1). The bone morphogenetic
proteins (BMPs)1 are potent
local factors that promote osteoblast differentiation during
development as well as during bone remodeling (2). The molecular events
downstream of BMP signaling that result in tissue-specific gene
expression and skeletal development have only been partially elucidated. The binding of BMPs to their receptors leads to the assembly of a receptor complex in which the type II receptor
phosphorylates and activates the type I receptor. As a result,
pathway-restricted SMADs are phosphorylated, leading to interactions
with the common mediator SMAD, smad4 (3). This complex is then
translocated to the nucleus, where it modulates transcription of target
genes. BMP signaling can also interfere with the effects of other
growth and differentiation factors. It has been demonstrated that BMP-2 treatment of mesangial cells prevents phosphorylation of a
transcription factor, Elk1, in response to platelet-derived growth
factor (PDGF) signaling. This effectively inhibits PDGF-induced
Elk-1-mediated transcription, and blocks PDGF-induced transcription of
c-fos, an Elk-1 target (4).
BMP-7 has been shown to be a potent inducer of Cbfa1, a
transcription factor belonging to the runt-domain gene
family that, in turn, regulates the expression of several genes in the
osteoblast (5). Although Cbfa1 expression is necessary, it alone is not sufficient for osteoblast differentiation (6). BMPs regulate the
program of osteoblast differentiation at several levels. They play a
critical role in the induction of several transcription factors that
promote differentiation, such as Cbfa1 (5) and Dlx5 (7), as well as increasing the expression of negative regulators, including Id (8) and Msx-2 (9). BMPs
have also been shown to induce the expression of follistatin
(10, 11) and noggin (2, 12), both of which are BMP-binding
proteins that serve to modulate the actions of locally synthesized
BMPs. A third level at which BMPs modulate osteoblast differentiation is exemplified by the induction of Tob by BMP-2. This
protein negatively regulates osteoblast proliferation and
differentiation at the level of BMP signaling by interacting with
receptor-regulated SMADs (13). Like BMPs, growth factors may
also play a dual role in regulating the program of osteoblast
differentiation. Notable in this respect is the observation that
fibroblast growth factor-1 stimulates the proliferation of immature
osteoblasts, whereas it limits the number of osteoblasts undergoing
terminal differentiation by promoting apoptosis in this latter cell
population (14).
Studies of cranial suture closure have provided critical in
vivo correlates for the in vitro studies demonstrating
the effects of growth and transcription factors on osteoblast
differentiation. Haploinsufficiency of Cbfa1 delays
intramembranous bone formation and ossification of cranial sutures,
which is consistent with the role of this transcription factor in
promoting osteoblast differentiation (15, 16); however, gain of
function mutations in Msx2 cause craniosynostosis (17).
Craniosynostosis is also seen in patients with mutations that increase
the activity of fibroblast growth factor receptor-2, notably Aperts and
Crouzons syndromes (18, 19).
Although the induction of Cbfa1 by BMPs has been shown to be
a pivotal event in endochondral bone formation, the identification of
genes induced prior to and after Cbfa1 will be essential to elucidate
other factors, the interaction of which is required for normal skeletal
differentiation. These factors are likely to play an important role in
skeletal homeostasis postnatally as well. Fracture healing models have
demonstrated that BMPs play a key role in skeletal remodeling, and
studies in transgenic mice have suggested an important role for Cbfa1
in skeletal homeostasis (20). In an analogous fashion, it is likely
that other factors involved in osteoblast differentiation will play a
pivotal role in the maintenance of skeletal homeostasis in the maturing
and aging skeleton. We, therefore, undertook studies to identify novel genes that are induced during the cascade of molecular events that
occur as a cell acquires the markers of a mature osteoblast, using an
in vitro cellular model. We have identified a novel protein kinase containing a nuclear localization signal and a glutamine-rich region characteristic of many transcription factors. When stably expressed, this kinase markedly attenuates the program of osteoblast differentiation recapitulated during prolonged culture of MC3T3-E1 cells.
 |
EXPERIMENTAL PROCEDURES |
Cell Culture--
The MLB13MYC clone 17 cells and rhBMP-2 were
kindly provided by Dr. Vicki Rosen (Genetics Institute, Cambridge, MA).
The cells were maintained in Dulbecco's modified Eagle's
medium supplemented with 10% heat-inactivated fetal bovine serum and
1% penicillin/streptomycin. At confluence, cells were treated with 200 ng/ml rhBMP-2 in Dulbecco's modified Eagle's medium with 1%
heat-inactivated fetal bovine serum and 1% penicillin/streptomycin,
adding fresh medium and rhBMP-2 daily as described previously
(21). Conditionally immortalized murine bone marrow stromal cells,
osteoblasts, and osteocytes (Dr. F. R. Bringhurst, Massachusetts
General Hospital, Boston, MA) were isolated and cultured as reported
previously (22, 23). Primary calvarial osteoblasts form 18.5-days
post-coital embryos were cultured as described previously (22).
MC3T3-E1 cells (ATCC) were cultured in -minimum Eagle's medium
supplemented with 10% fetal calf serum and 1%
penicillin/streptomycin. For experiments directed at addressing the
role of BIKe (BMP-2-Inducible
Kinase) on mineralization, medium was
supplemented with ascorbic acid and -glycerol phosphate (24). COS-7
cells (ATCC) were maintained in Dulbecco's modified Eagle's medium
supplemented with 10% fetal calf serum and 1%
penicillin/streptomycin.
Differential Display PCR--
Total RNA was isolated from
parallel cultures of MLB13MYC clone 17 cells, untreated, and treated
with 200 ng/ml rhBMP-2 for 72 h using Trizol reagent (Life
Technologies, Inc.). After treating with RNase-free DNaseI to eliminate
contaminating chromosomal DNA (MessageClean, GenHunter Corp.,
Nashville, TN), differential display PCR was performed using the
RNAimage system (GenHunter Corp.) according to the manufacturer's
instructions in the presence of [ 33P]dATP. The
radioactive products were resolved by electrophoresis on a denaturing
urea 6% polyacrylamide gel. After overnight autoradiography, differentially expressed bands were identified by comparison of the
products obtained using RNA from untreated and rhBMP-2-treated cells.
Products found to be reproducibly differentially expressed were
reamplified and subcloned into pGEM easy-T (Promega, Norwalk, CT).
Northern Analysis--
Total RNA was isolated from cultured
cells or mouse tissues using Trizol reagent (Life Technologies, Inc.)
according to the manufacturer's instructions. Electrophoresis of 10 µg of total RNA was performed in formaldehyde-agarose gels. The RNA
was transferred to nylon membranes (Biotrans ICN, Aurora, OH) by
capillary action. Hybridization was performed with QuikHyb Solution
(Life Technologies, Inc.). To confirm equal loading of RNA, the
membranes were also hybridized either with an antisense oligonucleotide
probe that recognizes the 18S rRNA subunit or with a
glyceraldehyde-3-phosphate dehydrogenase random primed probe.
Densitometric analysis was performed by scanning autoradiographs with a
Hewlett Packard ScanJet ADF scanner and determining image density with
Scion Image.
cDNA Library Construction and Screening--
After 72 h
of treatment with rhBMP-2 as described above, MLB13MYC clone 17 cell
mRNA was isolated using a Fast-Track mRNA purification kit
(Invitrogen, Carlsbad, CA). The mRNA was reverse-transcribed using
an (dT)-oligomer primer with 5' sequences that introduced an
XhoI site at the 3' end of the cDNA after second strand
synthesis (Lambda ZapII XR Library Construction kit, Stratagene, La
Jolla, CA). Following blunt-ending of the cDNA, ligating, and
phosphorylation of EcoRI adapters, the cDNA population
was digested with XhoI. Size fractionation was performed on
a Sepharose CL-2B column. Fractions containing cDNAs greater than 1 kilobase pairs in length were pooled and ligated into the Uni-Zap XR
vector (Stratagene). Following ligation, the phage were packaged with
Gigapak Gold Plus (Stratagene). Primary screening of 500,000 plaques
using the BIKe ddPCR product as a probe identified seven
potential positives. Tertiary and quaternary screening resulted in
plaque purification of six. Following in vivo excision of
the insert and pBluescript from the phage, the four longest positive
clones were characterized, and both strands were sequenced. Sequence
alignments were performed using SeqMan. DNA and protein homology
searches were performed using BLAST (NCBI). Peptide motifs were
identified using ExPASY.
Kinase Assay--
A fusion protein was produced by cloning the
kinase domain of BIKe, base pairs 239-1330 (amino acids 1-364) in
frame with glutathione S-transferase (GST) in the pGEX-4T-3
vector (Amersham Pharmacia Biotech) followed by expression in
Escherichia coli. The fusion protein (GST-BIKeKD) was
purified by affinity chromatography using glutathione-Sepharose
(Amersham Pharmacia Biotech). Kinase activity was determined by
incubating GST-BIKeKD with myelin basic protein (Sigma) and 5 µCi of
[ 32P]ATP in 50 mM Tris/HCl (pH 8.0), 25 mM MgCl2, 1 mM dithiothreitol, 20 µM ATP, 0.5 mM EGTA, and 10% glycerol (v/v).
Following incubation at 30 °C for 30 min, SDS-polyacrylamide gel
electrophoresis and autoradiography were performed.
Cell Transfection--
The 358-base pair fragment from 2952 to
3310 of BIKe (BIKeNLS) that contains the nuclear
localization signal was amplified by PCR and cloned in frame with the
C terminus of green fluorescent protein (GFP) in the
pcDNA3.1/NT-GFP-TOPO vector (Invitrogen). Transient transfection of
COS-7 cells was performed by electroporation. Fluorescence was
visualized by laser scanning confocal microscopy (LSM 510 Confocal
microscope, Carl Zeiss). Digital image analyses were performed using
Zeiss KS400 Image Analysis software. Staining with Hoescht 2495 dye was
performed to identify nuclei. The cDNA sequences encoding amino
acids 1-1087 of BIKe were inserted downstream of the CMV promoter in
pcDNA3.1 (Invitrogen) to generate pcDNA3.1/BIKe. MC3T3-E1 cells
were stably transfected (using calcium phosphate precipitation) with
pcDNA3.1/BIKe or pcDNA3.1 without cDNA insert (EV, empty vector). Pools of stably transfected clones were obtained by
selection with 300 µg/ml G418. After 14 days of G418 selection, pools
of 18 G418-resistant clones were obtained from the
pcDNA3.1/BIKe (MC3T3-E1-BIKe) and empty vector
(MC3T3-E1-EV) transfected cells. For all subsequent analyses, pools of
clones between passages 2 and 5 were used.
Alkaline Phosphatase Activity--
MC3T3-E1-BIKe and MC3T3-E1-EV
pooled clones were plated at a density of 5 × 103
cells/cm2 and cultured for periods ranging from 3 to 28 days. At each time point, cell lysates were incubated with assay buffer
containing 1.5 M 2-amino-2-methyl-1-propyl alcohol for 30 min at 37 °C using p-nitrophenyl phosphate as a
substrate. Alkaline phosphatase activity was quantitated by measuring
the release of p-nitrophenol by absorbance at 405 nm.
Mineralization Assay--
MC3T3-E1-BIKe and MC3T3-E1-EV pooled
clones were plated at a density of 5 × 103
cells/cm2 and cultured for periods ranging from 3 to 36 days. The formation of mineralized matrix nodules was determined by
alizarin red-S staining (25). In parallel experiments, calcium
accumulation in the matrix was quantitated by solubilizing the
deposited calcium with 0.6 N HCl overnight at room
temperature. The samples and a standard curve of calcium carbonate were
reacted with methylthymol blue and measured spectrophotometrically at
620 nm (26).
Statistical Analyses--
All values are expressed as mean ± S.E. Student's paired t test was used to evaluate
differences between MC3T3-E1-EV and MC3T3-E1-BIKe pools at each time
point. A p value <0.05 was considered statistically significant.
 |
RESULTS |
Confluent MLB13MYC clone 17 cells were induced to differentiate by
treatment with 200 ng/ml rhBMP-2 every 24 h for 72 h. This concentration and duration of treatment is sufficient for these cells
to acquire markers of osteoblast differentiation, including expression
of the osteocalcin gene (21). RNA isolated from cells, treated with
rhBMP-2 for 72 h, or left untreated was used for differential
display PCR. After overnight autoradiography, several bands
representing differentially expressed mRNAs were identified. A
prominently up-regulated band (Fig.
1A) was chosen for further characterization. This band was excised from the gel and used as a
probe for Northern blotting analyses following reamplification. The
mRNA encoded by the ddPCR product was ~7 kilobases in size, barely detectable in untreated MLBMYC clone 17 cells and markedly increased following 72 h of rhBMP-2 treatment (Fig.
1B). The peak level of expression of this transcript
post-BMP-2 treatment was later than that observed for Cbfa1 in this
cell line (peak level at 48 h, data not shown) and earlier than
induction of osteocalcin (first detected at 48 h post-treatment
(Ref. 21 and data not shown).

View larger version (78K):
[in this window]
[in a new window]
|
Fig. 1.
Differential display and northern
analyses. A, differential display of
cDNA from MLB13MYC clone 17 cells. An autoradiograph of ddPCR
products (cropped to specifically show the band of interest) was
generated using RNA isolated from parallel cultures left untreated (-)
or treated with 200 ng/ml rhBMP-2 (+) for 72 h after reaching
confluence. The arrow indicates the product that is
differentially expressed. B, time course of induction. An
autoradiograph of a Northern blot of MLB13MYC clone 17 cell RNA (10 µg) probed with the ddPCR product (upper panel) and
glyceraldehyde-3-phosphate dehydrogenase (GAPDH, lower
panel) is shown. Numbers correspond to hours of treatment
with 200 ng/ml rhBMP-2. C, expression of the mRNA in
cells of the osteoblastic lineage. An autoradiograph of a Northern blot
containing 10 µg of RNA in each lane, demonstrating expression of the
ddPCR product in conditionally immortalized osteocytes (C59)
and osteoblasts (F10), primary osteoblasts (POB),
and conditionally immortalized marrow stromal cells (MS1),
is shown. Lower panel, hybridization with an oligonucleotide
complementary to the 18S rRNA verified amount of RNA loaded.
|
|
To investigate whether the expression of this transcript was specific
to bone or was expressed in other mouse tissues, multitissue Northern
blotting analysis was performed. The mRNA corresponding to this
ddPCR product was expressed in spleen, kidney, lung, brain, heart,
diaphragm, and calvaria but not in liver (data not shown). The
transcript was also expressed in conditionally immortalized osteocytes
(C59), osteoblasts (F10), and marrow stromal
cells (MS1) as well as in primary osteoblasts
(POB) isolated from 18.5-days post-coital mouse embryos
(Fig. 1C).
Since the original 322-base pair sequence of the ddPCR product was not
present in the GenBankTM data base, a cDNA library was
constructed using mRNA isolated from rhBMP-2-treated MLBMYC clone
17 cells and screened to obtain the full-length cDNA sequence. Six
positive phage were isolated following which the cDNA inserts and
pBluescript were excised using ExAssit helper phage. The four clones
containing the longest cDNA inserts were further characterized.
Sequence analysis was obtained from both strands of at least two
independent cDNA inserts, and alignment was performed using
SeqMan. The 6.5-kilobase pair cDNA has an open reading frame
of 1138 amino acids (Fig. 2) with a
predicted molecular size of 126 kDa. Because the N-terminal region
contains a putative serine/threonine kinase domain, the novel gene was
named BIKe. Protein sequence analysis (PROSITE, Swiss
Institute of Bioinformatics) predicts a nuclear location for BIKe based
on the bipartite nuclear localization signal in the C-terminal region
of the peptide (underlined). Analysis of the BIKe protein
also reveals a glutamine-rich region, analogous to that found in
several transcription factors (27, 28) and thought to be important for
protein-protein interactions (29). A search of the BLAST protein data
base (NCBI) identified significant homology between BIKe and partial
human cDNA clones of unknown function. Furthermore, the kinase
domain of BIKe was evolutionarily conserved with significant homology
to Xenopus and Drosophila kinases (U58205 and
AF197910). Drosophila Numb-associated kinase was
identified as the most homologous protein of known function. However,
the absence of significant homology between the nonkinase domains of
BIKe and Numb-associated kinase suggests that BIKe is unlikely to be a
vertebrate homolog of this Drosophila kinase.

View larger version (61K):
[in this window]
[in a new window]
|
Fig. 2.
Deduced amino acid sequence of BIKe. The
kinase domain is shown in bold, and the putative nuclear
localization signal is underlined.
|
|
To demonstrate that the BIKe kinase domain was functional, in
vitro kinase assays were performed. A fusion protein of GST and
the BIKe kinase domain (GST-BIKeKD) was expressed in E. coli and purified. Following incubation of GST-BIKeKD with myelin basic protein and [ 32P]ATP, labeled proteins corresponding
to GST-BIKeKD and myelin basic protein were resolved by
SDS-polyacrylamide gel electrophoresis. Autoradiography of the gel
demonstrated the ability of BIKe to autophosphorylate (Fig.
3B, lanes 2 and
4; GST-BIKeKD) as well as to phosphorylate myelin
basic protein (Fig. 3B, lane 2; MBP), a general protein kinase substrate. A GST fusion protein encoding a
transcription factor (30) was unable to phosphorylate itself or myelin
basic protein (Fig. 3B, lane 6). After thrombin
cleavage to remove GST, the BIKeKD retained its ability to
autophosphorylate; however, heat inactivation of GST-BIKeKD prevented
phosphorylation (Fig. 3B, lane 3).

View larger version (79K):
[in this window]
[in a new window]
|
Fig. 3.
Kinase activity of GST-BIKeKD.
A, Coomassie stain of the SDS-polyacrylamide gel shown in
panel B. B, autoradiograph of SDS-polyacrylamide
gel resolving products of kinase reactions. Lane 1,
molecular size markers in kDa to left; lane 2,
GST-BIKeKD and myelin basic protein (MBP); lane
3, GST-BIKeKD heated to 95 °C prior to incubation with MBP;
lane 4, GST-BIKeKD alone; lane 5, MBP alone;
lane 6, a GST fusion protein encoding the transcription
factor BTEB3 incubated with MBP.
|
|
To evaluate the function of the bipartite nuclear localization signal
(NLS) in the C-terminal region of BIKe, the cDNA sequences encoding amino acids 906-1025 were inserted in frame to that encoding GFP. As shown in Fig. 4B, the
NLS of BIKe can direct GFP expression (left upper panel) to
the nucleus of COS-7 cells (visualized with Hoescht dye in the
right upper panel), whereas GFP expressed without the
BIKeNLS remains diffuse (Fig. 4A, left upper
panel).

View larger version (48K):
[in this window]
[in a new window]
|
Fig. 4.
The BIKe nuclear
localization signal can direct GFP to the nucleus. COS-7 cells
were transfected with a vector containing a GFP control plasmid
(A) or GFP fused to the BIKeNLS (B). Upper
left panel, fluorescent confocal microscopy. Nuclei were
visualized with Hoechst dye (upper right panel). Lower
panels, light microscopy.
|
|
To identify a role for this novel kinase in osteoblast differentiation,
MC3T3-E1 cells were transfected with either pcDNA3.1/BIKe Fig. 5 (panels B and
C, lane B) or pcDNA3.1 lacking insert
(lane EV). This cell line was chosen because when plated at
low density, the MC3T3-E1 cells have features of a preosteoblastic
cell. When left in culture for approximately a month, these cells
acquire characteristics of a fully differentiated osteoblast without
the addition of exogenous differentiating agents such as BMPs. It is
also notable that the endogenous mRNA encoding BIKe in this cell
line increases as the program of osteoblast differentiation is
recapitulated with prolonged culture with peak levels seen at 20 days
in culture (Fig. 5, panel A). Several classical markers of
osteoblast differentiation were evaluated in the MC3T3-E1-BIKe and
MC3T3-E1-EV clones. Although no change was observed in the expression
of type I collagen (not shown) or CbfaI (Fig. 5, panel B) in
the MC3T3-E1-BIKe pooled clones relative to the MC3T3-E1-EV pools,
there was attenuation in the expression of osteocalcin mRNA in the
MC3T3-E1-BIKe pooled clones (Fig. 5, panel C), including a
decrease in the peak level of expression at 20 days in culture, when
compared with the MC3T3-E1-EV pooled clones. The acquisition of
alkaline phosphatase activity was also dramatically impaired in the
MC3T3-E1-BIKe clones relative to the MC3T3-E1-EV clones (Fig.
6). The end point of osteoblast
differentiation is considered to be the formation of a mineralized
matrix. The MC3T3-E1-BIKe clones demonstrated a dramatic impairment in
mineral deposition into the culture, as assessed by alizarin
red-S staining (not shown) and quantitation of calcium deposited into
the matrix by methylthymol blue analysis (26) (Fig.
7).

View larger version (59K):
[in this window]
[in a new window]
|
Fig. 5.
Northern analyses of mRNA isolated from
MC3T3-E1 cells. At the indicated time (days) post-plating,
RNA was isolated from the MC3T3-E1 cells; 10 µg was subjected to
Northern analysis and probed with the BIKe cDNA.
Panel A, levels of mRNA encoding the endogenous
BIKe transcript increase with differentiation. Panel
B, the mRNA encoding Cbfa1 is not altered in the
MC3T3-E1-BIKe (lane B) pooled clones relative to the
MC3T3-E1-EV (lane EV) pooled clones (B).
Panel C, the expression of osteocalcin (OC)
mRNA is decreased in MC3T3-E1-BIKe (lane B) relative to
MC3T3-E1-EV (lane EV) pooled clones, including the peak
level of expression seen at 20 days. Autoradiographs are representative
of results obtained in three independent experiments.
|
|

View larger version (19K):
[in this window]
[in a new window]
|
Fig. 6.
Assessment of alkaline phosphatase activity
in pooled clones. Alkaline phosphatase activity is
decreased from days 7 to 28 in culture (p < 0.008 at
all points indicated) as is the peak level of expression in
MC3T3-E1-BIKe compared with MC3T3-E1-EV (control) pooled
clones. Data are representative of those obtained in three independent
experiments. wt, wild type; PNPP, p-nitrophenyl
phosphate.
|
|

View larger version (30K):
[in this window]
[in a new window]
|
Fig. 7.
Calcium deposition into the cultures of
pooled clones. Mineral deposition into the cultures, as assessed
by calcium content, is markedly delayed and diminished in the
MC3T3-E1-BIKe pooled clones compared with the MC3T3-E1-EV
(control) pooled clones (p < 0.003 at all
time points indicated). Data are representative of those obtained in
three independent experiments.
|
|
 |
DISCUSSION |
To identify factors regulated by BMP-2 that contribute to the
development and maintenance of a normal skeleton, we performed differential display PCR analyses, which led to the identification of a
gene encoding a novel protein kinase. Investigations aimed at
identifying BMP-regulated genes have been performed in various cellular
systems. Studies directed at identifying immediate early genes
regulated by BMPs in embryonic stem cells have demonstrated that
several regulators of skeletal development are regulated by BMP-4 in
these cells. Notably, the homeobox genes, Msx-1 and Msx-2, are rapidly induced, as is JunB (31). The
negative regulators of helix-loop-helix transcription factors,
Id1, Id2, and Id3, were also found to
be BMP-responsive in embryonic stem cells (31). In contrast to these
investigations, our studies were biased toward identification of distal
actions of BMP-2 because the initial ddPCR reaction was performed using
RNA isolated from cells treated with BMP-2 for 72 h.
The cell line used for our studies was a prechondroblastic cell line
that responds to BMP-2 with an increase in Cbfa1 mRNA levels, similar to that seen in BMP-2-treated immortalized articular and primary costal chondrocyte cultures (32) and pluripotential mesenchymal cells (5). During prolonged treatment with BMP-2, the
MLB13MYC clone 17 cell line loses markers of a prechondroblast and
acquires markers characteristic of an osteoblast (21). The mRNA
encoding the novel kinase we identified increases as the osteoblast
differentiation program is recapitulated during prolonged culture of
MC3T3-E1 cells, supporting the hypothesis that its induction by BMP-2
in the MLB13MYC clone 17 cells parallels its expression during
osteoblast differentiation. However, BIKe attenuates rather than
promotes the osteoblast differentiation program of the MC3T3-E1 cells,
most dramatically affecting the level of alkaline phosphatase activity
and osteocalcin mRNA as well as inhibiting mineral
deposition into the cultures. Several studies of osteoblast differentiation have focused on factors that promote the
differentiation of pluripotent mesenchymal stromal cells into
osteoblasts. It has been shown that Cbfa 1 is required for the
development of an osseous skeleton and regulates the expression of many
osteoblast genes (5, 15, 16, 33). However, stable transfection of BIKe
did not change the pattern of Cbfa1 expression in the MC3T3-E1 cells,
suggesting that the mechanism of BIKe action is independent of or
downstream to Cbfa1.
Little is known about the factors that prevent or retard the commitment
of pluripotential mesenchymal stromal cells to the osteoblast lineage;
however, the mechanisms by which these cells are diverted into
alternative pathways has largely been clarified. It has been
demonstrated that the nuclear receptor peroxisome proliferator-activated receptor- plays a pivotal role in directing these stromal cells to the adipocyte lineage (34) and that several helix-loop-helix transcription factors are involved in the
differentiation of these cells along the myogenic pathway (35). Our
studies, however, were performed in cells that had already acquired
markers of chondroblasts (the MLB13MYC clone 17 cells are
prechondroblastic) or osteoblasts (MC3T3-E1 cells). These studies were
not directed at addressing the effect of BIKe on the commitment of
stromal cells to the osteoblast versus adipocyte or myocyte
pathway; however, our finding that BIKe is expressed in marrow stromal
cells does not exclude this possibility. The data presented here are
consistent with BIKe playing a role in attenuating differentiation of
and mineral deposition by the maturing osteoblast. The induction of BIKe during osteoblast differentiation may serve as a brake
to control the rate of osteoblast differentiation, which is critical for normal skeletal development and morphogenesis. Negative regulation almost certainly plays a key role in skeletal development. The program
of osteoblast differentiation involves an early proliferative phase not
associated with the expression of markers of terminal differentiation
or mineralized matrix formation (36-38). Although the laying down of
mineralized matrix is considered to be the terminal phase of osteoblast
differentiation, this is not the major in vivo role of the
lining osteoblasts or osteocytes. Therefore, factors that seem to
attenuate osteoblast differentiation in traditional assays, such as the
MC3T3-E1 and rat calvarial cells, may actually play a role in the
transition from an active matrix-synthesizing osteoblast to a cell that
serves a different function in vivo. Notable in this respect
is the observation that conditionally immortalized osteocytes express
the BIKe transcript.
The kinase activity, nuclear localization signal, and glutamine-rich
domain of BIKe suggest potential molecular mechanisms by which this
novel protein influences osteoblast differentiation. Phosphorylation is
a critical posttranslational modification that regulates the activity
of several proteins involved in signal transduction, cellular
proliferation, and gene transcription. The presence of a nuclear
localization signal and of a glutamine-rich region, often found in
transcription factors, raises the interesting question as to whether
BIKe acts a transcription factor. Alternatively, the nuclear
localization of this protein could reflect its role as a kinase
involved in phosphorylation of histones and/or transcription factors
with protein-protein interactions mediated by the glutamine-rich region. In addition to being present in numerous transcription factors,
glutamine-rich regions have a high propensity to form self-propagating
amyloid fibrils (29). They are also hot spots for the trinucleotide
repeat expansions involved in the pathogenesis of several human
diseases, including Huntington's disease, Kennedy's disease, and
several spinocerebellar ataxias. Currently, however, there are no
diseases linked to chromosome 4q21 (the locus for the human homolog of
BIKe, NCBI) to suggest that BIKe is involved in the
pathogenesis of human disease. The identification of potential BIKe
substrates and characterization of its other functional domains will
serve to define the molecular mechanism by which this novel kinase
modulates the program of osteoblast differentiation.
 |
ACKNOWLEDGEMENTS |
We thank Dr. V. Rosen for the MLB13MYC clone
17 cells and rhBMP-2 and Dr. F. R. Bringhurst for the
conditionally immortalized murine marrow stromal cells, osteoblasts,
and osteocytes.
 |
FOOTNOTES |
*
This work was supported by National Institutes of Health
Grant DK-36597 (to M. B. D.), National Institutes of Health and the American Society of Bone and Mineral Research Grant AR-45011 (to A. E. K.), and the Mayo Foundation (to A. E. K.).The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
The nucleotide sequence(s) reported in this paper has been submitted to the GenBankTM/EMBL Data Bank with accession number(s) AYe50249.
§
Both authors contributed equally to this work.
To whom correspondence should be sent: Endocrine Unit,
Massachusetts General Hospital, Harvard Medical School, Wellman 503, 50 Blossom St. Tel.: 617-726-3966; Fax: 617-726-7543; E-mail: demay@helix.mgh.harvard.edu.
Published, JBC Papers in Press, August 10, 2001, DOI 10.1074/jbc.M106163200
 |
ABBREVIATIONS |
The abbreviations used are:
BMP, bone
morphogenic protein;
BIKe, BMP-2-inducible kinase;
ddPCR, differential display polymerase chain reaction;
GST, glutathione
S-transferase;
GFP, green fluorescent protein;
NLS, nuclear
localization signal;
EV, empty vector;
KD, kinase domain.
 |
REFERENCES |
| 1.
|
Ducy, P.,
Schinke, T.,
and Karsenty, G.
(2000)
Science
289,
1501-1504[Abstract/Free Full Text]
|
| 2.
|
Reddi, A.
(1992)
Curr. Biol.
4,
850-855
|
| 3.
|
Massague, J.
(1998)
Annu. Rev. Biochem.
67,
753-791[CrossRef][Medline]
[Order article via Infotrieve]
|
| 4.
|
Ghosh-Choundhury, G.,
Kim, Y.-S.,
Simon, M.,
Wozney, J.,
Harris, S.,
Gosh-Choundhury, N.,
and Abboud, H.
(1999)
J. Biol. Chem.
274,
10897-10902[Abstract/Free Full Text]
|
| 5.
|
Ducy, P.,
Zhang, R.,
Geoffroy, V.,
Ridall, A. L.,
and Karsenty, G.
(1997)
Cell
89,
747-754[CrossRef][Medline]
[Order article via Infotrieve]
|
| 6.
|
Lee, M.-H.,
Javed, A.,
Kim, H.-J.,
Shin, H.-I.,
Gutierrez, S.,
Choi, J.-Y.,
Rosen, V.,
Stein, J.,
van Wijnen, A.,
Stein, G. S.,
Lian, J.,
and Ryoo, H.-M.
(1999)
J. Cell. Biochem.
73,
114-125[CrossRef][Medline]
[Order article via Infotrieve]
|
| 7.
|
Miyama, K.,
Yamada, G.,
Yamamoto, T.,
Takagi, C.,
Miyado, K.,
Sakai, M.,
Ueno, N.,
and Shibuya, H.
(1999)
Dev. Biol.
208,
123-133[CrossRef][Medline]
[Order article via Infotrieve]
|
| 8.
|
Ogata, T.,
Wozney, J.,
Benezra, R.,
and Noda, M.
(1993)
Proc. Natl. Acad. Sci. U. S. A.
90,
9219-9222[Abstract/Free Full Text]
|
| 9.
|
Monsoro-Burq, A.,
Duprez, D.,
Watanabe, Y.,
Bontoux, M.,
Vincent, C.,
Brickell, P.,
and LeDouarin, N.
(1996)
Development
122,
3607-3616[Abstract]
|
| 10.
|
Fainsod, A.,
Deissler, K.,
Yelin, R.,
Marom, K.,
Epstein, M.,
Pillemer, G.,
Steinbeisser, H.,
and Blum, M.
(1997)
Mech. Dev.
63,
39-50[CrossRef][Medline]
[Order article via Infotrieve]
|
| 11.
|
Kearns, A.,
and Demay, M. B.
(2000)
J. Cell. Biochem.
79,
80-88[CrossRef][Medline]
[Order article via Infotrieve]
|
| 12.
|
Re'em-Kalma, Y.,
Lamb, T.,
and Frank, D.
(1995)
Proc. Natl. Acad. Sci. U. S. A.
92,
12141-12145[Abstract/Free Full Text]
|
| 13.
|
Yoshida, Y.,
Tanaka, S.,
Umemori, H.,
Minowa, O.,
Usui, M.,
Ikematsu, N.,
Hosoda, E.,
Imamura, T.,
Kuno, J.,
Yamashita, T.,
Miyazono, K.,
Noda, M.,
Tetsuo, N.,
and Yamamoto, T.
(2000)
Cell
103,
1085-1097[CrossRef][Medline]
[Order article via Infotrieve]
|
| 14.
|
Mansukhani, A.,
Bellosta, P.,
Sahni, M.,
and Basilico, C.
(2000)
J. Cell Biol.
149,
1297-1308[Abstract/Free Full Text]
|
| 15.
|
Mundlos, S.,
Otto, F.,
Mundlos, C.,
Mulliken, J. B.,
Aylsworth, A. S.,
Albright, S.,
Lindhout, D.,
Cole, W. G.,
Henn, W.,
Knoll, J. H. M.,
Owen, M. J.,
Mertelsmann, R.,
Zabel, B. U.,
and Olsen, B. R.
(1997)
Cell
89,
773-779[CrossRef][Medline]
[Order article via Infotrieve]
|
| 16.
|
Otto, F.,
Thornell, A. P.,
Crompton, T.,
Denzel, A.,
Gilmour, K. C.,
Rosewell, I. R.,
Stamp, G. W. H.,
Beddington, R. S. P.,
Mundlos, S.,
Olsen, B. R.,
Selby, P. B.,
and Owen, M. J.
(1997)
Cell
89,
765-771[CrossRef][Medline]
[Order article via Infotrieve]
|
| 17.
|
Jabs, E.,
Muller, U.,
Li, X.,
Ma, L.,
Luo, W.,
Haworth, I.,
Klisak, I.,
Sparkes, R.,
Warman, M.,
and Mulliken, J.
(1993)
Cell
75,
443-450[CrossRef][Medline]
[Order article via Infotrieve]
|
| 18.
|
Anderson, J.,
Burns, H.,
Enriquez-Harris, P.,
Wilkie, A.,
and Health, J.
(1998)
Hum. Mol. Genet.
7,
1475-1483[Abstract/Free Full Text]
|
| 19.
|
Neilson, K.,
and Friesel, R.
(1995)
J. Biol. Chem.
270,
26037-40[Abstract/Free Full Text]
|
| 20.
|
Ducy, P.,
Starbuck, M.,
Priemel, M.,
Shen, J.,
Pinero, G.,
Geoffroy, V.,
Amling, M.,
and Karsenty, G.
(1999)
Genes Dev.
13,
1025-1036[Abstract/Free Full Text]
|
| 21.
|
Rosen, V.,
Nove, J.,
Song, J. J.,
Thies, R. S.,
Cox, K.,
and Wozney, J. M.
(1994)
J. Bone Miner. Res.
9,
1759-1768[Medline]
[Order article via Infotrieve]
|
| 22.
|
Divieti, P.,
Lanske, B.,
Kronenberg, H. M.,
and Bringhurst, F. R.
(1998)
J. Bone Miner. Res.
13,
1835-1843[CrossRef][Medline]
[Order article via Infotrieve]
|
| 23.
|
Liu, B.,
Guo, J.,
Lanske, B.,
Divieti, P.,
Kronenberg, H. M.,
and Bringhurst, F. R.
(1998)
Endocrinology
139,
1952-1964[Abstract/Free Full Text]
|
| 24.
|
Quarles, L. D.,
Wenstrup, R.,
Castillo, S.,
and Drezner, M.
(1991)
Endocrinology
128,
3144-3151[Abstract/Free Full Text]
|
| 25.
|
Gori, F.,
Thomas, T.,
Hicok, K.,
Spelberg, T.,
and Riggs, B. L.
(1999)
J. Bone Miner. Res.
14,
1522-1535[CrossRef][Medline]
[Order article via Infotrieve]
|
| 26.
|
Gindler, E.,
and King, J.
(1972)
Am. J. Clin. Pathol.
58,
376-382[Medline]
[Order article via Infotrieve]
|
| 27.
|
Smith, R.,
and Johnson, A.
(2000)
Trends Biochem. Sci.
25,
325-330[CrossRef][Medline]
[Order article via Infotrieve]
|
| 28.
|
Das, D.,
and Scovell, W.
(2001)
J. Biol. Chem.
276,
32597-32605[Abstract/Free Full Text]
|
| 29.
|
Michelitsch, M.,
and Weissman, J.
(2000)
Proc. Natl. Acad. Sci. U. S. A.
97,
11910-11915[Abstract/Free Full Text]
|
| 30.
|
Martin, K.,
Cooper, W.,
Metcalfe, J.,
and Kemp, P.
(2000)
Biochem. J.
345,
529-533
|
| 31.
|
Hollnagel, A.,
Oehlmann, V.,
Heymer, J.,
Ruther, U.,
and Nordheim, A.
(1999)
J. Biol. Chem.
274,
19838-19845[Abstract/Free Full Text]
|
| 32.
|
Takazawa, Y.,
Tsuji, K.,
Nifuji, A.,
Kurosawa, H.,
Ito, Y.,
and Noda, M.
(2000)
J. Endocrinol.
165,
579-586[Abstract]
|
| 33.
|
Komori, T.,
Yagi, H.,
Nomura, S.,
Yamaguchi, A.,
Sasaki, K.,
Deguchi, K.,
Shimizu, Y.,
Bronson, R. T.,
Gao, Y.-H.,
Inada, M.,
Sato, M.,
Okamoto, R.,
Kitamura, Y.,
Yoshiki, S.,
and Kishimoto, T.
(1997)
Cell
89,
755-764[CrossRef][Medline]
[Order article via Infotrieve]
|
| 34.
|
Tontonoz, P.,
Hu, E.,
Graves, R. A.,
Budavari, A. I.,
and Spiegelman, B. M.
(1994)
Genes Dev.
8,
1224-1234[Abstract/Free Full Text]
|
| 35.
|
Tajbakhsh, S.,
Rocancourt, D.,
Cossu, G.,
and Buckingham, M.
(1997)
Cell
89,
127-138[CrossRef][Medline]
[Order article via Infotrieve]
|
| 36.
|
Malaval, L.,
Modrowski, D.,
Gupta, A.,
and Aubin, J.
(1994)
J. Cell. Physiol.
158,
555-572[CrossRef][Medline]
[Order article via Infotrieve]
|
| 37.
|
Malaval, L.,
Liu, F.,
Roche, P.,
and Aubin, J.
(1999)
J. Cell. Biochem.
74,
616-627[CrossRef][Medline]
[Order article via Infotrieve]
|
| 38.
|
Pockwinse, S.,
Stein, J.,
Lian, J.,
and Stein, G.
(1995)
Exp. Cell Res.
216,
244-260[CrossRef][Medline]
[Order article via Infotrieve]
|
Copyright © 2001 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
F. Palm, M. L. Onozato, Z. Luo, and C. S. Wilcox
Dimethylarginine dimethylaminohydrolase (DDAH): expression, regulation, and function in the cardiovascular and renal systems
Am J Physiol Heart Circ Physiol,
December 1, 2007;
293(6):
H3227 - H3245.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Jha, N. R. Agostinelli, S. K. Mishra, P. A. Keyel, M. J. Hawryluk, and L. M. Traub
A Novel AP-2 Adaptor Interaction Motif Initially Identified in the Long-splice Isoform of Synaptojanin 1, SJ170
J. Biol. Chem.,
January 16, 2004;
279(3):
2281 - 2290.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. S. Gammill and M. Bronner-Fraser
Genomic analysis of neural crest induction
Development,
March 14, 2003;
129(24):
5731 - 5741.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Zhao, J.E. Berry, and M.J. Somerman
Bone Morphogenetic Protein-2 Inhibits Differentiation and Mineralization of Cementoblasts in vitro
Journal of Dental Research,
January 1, 2003;
82(1):
23 - 27.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Z.-J. Shen, T. Nakamoto, K. Tsuji, A. Nifuji, K. Miyazono, T. Komori, H. Hirai, and M. Noda
Negative Regulation of Bone Morphogenetic Protein/Smad Signaling by Cas-interacting Zinc Finger Protein in Osteoblasts
J. Biol. Chem.,
August 9, 2002;
277(33):
29840 - 29846.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2001 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|